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Abstract
The incidence and mortality of colorectal cancer (CRC) is higher in African Americans (AAs) than other ethnic groups in the
U. S., but reasons for the disparities are unknown. We performed gene expression profiling of sporadic CRCs from AAs vs.
European Americans (EAs) to assess the contribution to CRC disparities. We evaluated the gene expression of 43 AA and 43
EA CRC tumors matched by stage and 40 matching normal colorectal tissues using the Agilent human whole genome 4x44K
cDNA arrays. Gene and pathway analyses were performed using Significance Analysis of Microarrays (SAM), Ten-fold cross
validation, and Ingenuity Pathway Analysis (IPA). SAM revealed that 95 genes were differentially expressed between AA and
EA patients at a false discovery rate of #5%. Using IPA we determined that most prominent disease and pathway
associations of differentially expressed genes were related to inflammation and immune response. Ten-fold cross validation
demonstrated that following 10 genes can predict ethnicity with an accuracy of 94%: CRYBB2, PSPH, ADAL, VSIG10L,
C17orf81, ANKRD36B, ZNF835, ARHGAP6, TRNT1 and WDR8. Expression of these 10 genes was validated by qRT-PCR in an
independent test set of 28 patients (10 AA, 18 EA). Our results are the first to implicate differential gene expression in CRC
racial disparities and indicate prominent difference in CRC inflammation between AA and EA patients. Differences in
susceptibility to inflammation support the existence of distinct tumor microenvironments in these two patient populations.
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Introduction
Colorectal cancer (CRC) remains the most common gastroin-
testinal cancer in the United States, despite recent improvements
in the diagnosis and treatment of the disease. The incidence and
mortality rates of CRC for African Americans (AAs) are higher
than in the U.S. general population [1,2]. Many epidemiologic
and genetic investigations have focused on AAs [3,4,5,6] with the
goal of deciphering the reasons for such disparities. Whereas one
cannot discount the contribution of socioeconomic factors, such as
a more advanced stage of disease at diagnosis in AAs, other
biological factors also contribute to the progression of colon cancer
[4]; [7]. However, a biological basis for the existence of a more
aggressive CRC in African American patients remains to be
further elucidated. Genomic instability is a crucial feature in tumor
development and there are at least 3 distinct pathways in CRC
pathogenesis: chromosomal instability (CIN), microsatellite insta-
bility (MSI), and CpG island methylator phenotype pathways
(CIMP) [8,9]. Any or all of these pathways may contribute to a
more aggressive CRC biology in African Americans. Recent
genome-wide association studies in CRC have shown not only
strong evidence for common single nucleotide polymorphism
(SNP) association in a number of genes and chromosomal regions,
but also genetic heterogeneity in CRC association in AAs versus
EAs [4,10,11,12,13]. Different incidence of MSI and different level
of methylation for functionally very relevant genes were also
reported as a possible factors in CRC racial disparities [8,14,15].
We hypothesized that the gene expression profiles of CRC in
African-American and European-American patients may reveal
biological differences between the two populations that could
explain the more aggressive cancer phenotype in African-
Americans. Thus, we performed genome-wide gene expression
profiling in a large set of tumor samples that were matched for
selected clinical variables. We analyzed our results on gene and
pathway levels to identify key differences in tumor biology between
African-American and European-American patients.
Methods
Patients
One hundred and fourteen tumors (86 included in original
analysis and 28 for validation study) and 40 normal tissues from de-
identified CRC patients were obtained from the Institutional
Research Board (IRB) approved University of North Carolina
(UNC) Tissue Procurement Facility after UNC School of Medicine
IRB approval for this study. Written informed consent was obtained
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at the time of operation and snap frozen in liquid nitrogen. Patients
with known familial adenomatous polyposis and hereditary non-
polyposis CRC were excluded. De-identified data including race,
tumor,node and metastasis (TNM), grade or differentiation,margin
status, and survival were available for the majority of patients.
RNA Isolation and Microarray Hybridization
All RNA isolation and hybridization was performed on Agilent
(Agilent Technologies, Santa Clara, CA) human whole genome
4X44 K DNA microarrays at UNC. RNA was extracted from
macrodissected snap-frozen tumor samples using All prep Kits
(Qiagen, Valencia, CA) and quantified using Nanodrop spectro-
photometry (ThermoScientific, Wilmington, DE). RNA quality
was assessed with the use of the Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA). RNA was selected for hybrid-
ization using RNA integrity number and by inspection of the 18S
and 28S ribosomal RNA. Similar RNA quality was selected across
samples. One microgram of RNA was used as a template for
cDNA preparation prior to hybridization to Agilent 4X44 K
whole human genome arrays. cDNA was labeled with Cy5-dUTP
and a reference control (Stratagene; Catalog Number # 740000;
Agilent Technologies, Santa Clara, CA; [16] was labeled with
Cy3-dUTP using the Agilent low RNA input linear amplification
kit and hybridized overnight at 65uC to Agilent 4X44 K whole
human genome arrays. Arrays were washed and scanned using an
Agilent scanner (Agilent Technologies, Santa Clara, CA).
All microarray data are in MIAME compliant form and raw
and processed data has been deposited in the Gene Expression
Omnibus (GEO); see http://www.ncbi.nlm.nih.gov/geo/, acces-
sion number: GSE28000.
Microarray and statistical analysis
All array data were normalized using LOWESS normalization.
Data were excluded for genes with poor spot quality or genes that
did not have a mean intensity greater than 10 for one of the two
channels (green and red) in at least 70% of the experiments. The
log2 ratio of the mean red intensity over mean green intensity was
calculated for each gene followed by LOWESS normalization
[17]. Missing data were imputed using the k-nearest neighbors
imputation (KNN) with k=10 [18]. Genes that were significantly
up- or down-regulated were identified using Significance Analysis
of Microarrays (SAM) [19]. SAM assigns a score to each gene on
the basis of a change in gene expression relative to the standard
deviation of repeated measurements. For genes with scores greater
than an adjustable threshold, SAM uses permutations of the
repeated measurements to estimate the percentage of genes
identified by chance – the false discovery rate (FDR). Analysis
parameters (Delta) were set to result in FDR#5%.
Network and gene ontology analysis
Differentially expressed genes were investigated for network and
gene functional interrelation by Ingenuity Pathways Analysis (IPA)
software (Ingenuity Systems, www.ingenuity.com; [20]. IPA scans
the set of input genes to identify networks by using Ingenuity
Pathways Knowledge Base for interactions between identified
‘Focus Genes’, in this study, the differentially expressed genes
between AA and EA and known and hypothetical interacting
genes stored in the knowledge base in IPA software was used to
generate a set of networks with a maximum network size of 35
genes/proteins. Networks are displayed graphically as genes/gene
products (‘nodes’) and the biological relationships between the
nodes (‘edges’). All edges are from canonical information stored in
the Ingenuity Pathways Knowledge Base. In addition, IPA
computes a score for each network according to the fit of the
user’s set of significant genes. The score indicates the likelihood of
the Focus Genes in a network from Ingenuity’s knowledge base
being found together due to random chance. A score of 3, as the
cutoff for identifying gene networks, indicates that there is only a
1/1000 chance that the focus genes shown in a network are due to
random chance. Therefore, a score of 3 or higher indicates a
99.9% confidence level to exclude random chance.
Ten-fold Cross Validation (Ten-f-CV)
Ten-f-CVanalysis[21] wasused to selectsmallerrepresentativeset
of genes for validation study by qRT-PCR. Using Ten-f-CV analysis
we identified 10 genes that can predict the ethnicity of the patient for
whom the array was done with an error rate of 6%, suggesting that
these 10 genes are representative of the entire gene list.
Quantitative real-time PCR
Validation of microarray results was performed on 28 CRC
patients (10 AA, and 18 EA). Ten differentially expressed genes
(identified by SAM and selected using the Ten-f-CV method) were
validated by qRT-PCR. The hydroxymethylbilane synthase
(HMBS) gene served as the housekeeping gene [22]. qRT-PCR
was performed in duplicates using SYBR Green Gene Expression
Assays (Applied Biosystems, Forester City, CA), which include pre-
optimized primer sets specific for the genes being validated [23].
The validated genes were: Crystalline, beta B2 (CRYBB2),
phosphoserine phosphatase homologue (PSPH), Adenosine deam-
inase-like (ADAL), V-set and immunoglobulin domain containing
10 like (VSIG10L), Chromosome 17 open reading frame 81
(C17orf81), Ankyrin repeat domain 36B (ANKRD36B). Zinc
finger protein 83 (ZNF83), Rho GTPase activating protein 6
(ARHGAP6), WD repeat domain 8 (WDR8), TRNA nucleotidyl
transferase, CCA-adding, 1 (TRNT1), and HMBS. Data were
collected using the ABI PRISM 7500 sequence detection system
(Applied Biosystems, Forster City, CA). qRT-PCR data for each
sample were normalized using expression of the housekeeping
gene HMBS. Graphs were prepared from normalized data relative
to HMBS. Statistical analysis of these data was performed with a
Table 1. Clinical characteristics of the study population.
Characteristics Whites (n=43) Blacks (n=43) p-Value*
No. % No. %
Mean Age (y) 67 n/a 62.7 n/a 0.18**
Gender
Male 19 44.19 25 58.14
Female 24 55.81 18 41.86 0.28
Location
Right 17 39.53 22 51.16
Left 21 48.83 21 48.83
Unknown 5 11.62 0 0.00 0.06
Tumor Stage
1 4 9.30 4 9.30
2 16 37.21 16 37.21
3 8 18.60 8 18.60
4 15 34.88 15 34.88 1.00
*p-values based on Fisher’s exact test.
**p-value based on t-test.
doi:10.1371/journal.pone.0030168.t001
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No. Gene ID Gene Name Gene Title Chromosome Location
Fold
Change
1 1415 CRYBB2 Crystallin,beta B2 Crystallin,betaB2 22q11.2-q12.1|22q11.23 3.10
2 5723 PSPH Phosphoserinephosphatase 7p15.2-p15.1 3.38
3 116285 ACSM1 Acyl-CoAsynthetase medium-chain family member 1 16p12.3 2.47
4 23008 KLHDC10 Kelchdomain containing 10 7q32.2 1.48
5 90865 IL33 Interleukin33 9p24.1 3.08
6 6231 RPS26 Ribosomalprotein S26 12q13 1.63
7 401081 FLJ22763 Hypotheticalgene supported by AK026416 3q13.13 4.69
8 10780 ZNF234 Zincfinger protein 234 19q13.31 2.09
9 2863 GPR39 Gprotein-coupled receptor 39 2q21-q22 1.58
10 60439 TTTY2 Testis-specifictranscript, Y-linked 2 (non-protein coding) Yp11.2 1.55
11 27012 KCNV1 Potassiumchannel, subfamily V, member 1 8q22.3-q24.1 2.58
12 55020 TTC38 Tetratricopeptiderepeat domain 38 22q13 1.67
13 256380 SCML4 Sexcomb on midleg-like 4 (Drosophila) 6q21 2.90
14 5062 PAK2 P21protein (Cdc42/Rac)-activated kinase 2 3q29 1.43
15 540 ATP7B ATPase,Cu++ transporting, beta polypeptide 13q14.3 1.66
16 23562 CLDN14 Claudin14 21q22.3 2.35
17 10911 UTS2 Urotensin2 1p36 2.45
18 1416 CRYBB2P1 Crystallin,beta B2 pseudogene 1 22q11.2-q12.1 1.59
19 55282 LRRC36 Leucinerich repeat containing 36 16q22.1 2.45
20 348013 FAM70B Familywith sequence similarity 70, member B 13q34 1.48
21 81839 VANGL1 Vang-like1 (van gogh, Drosophila) 1p11-p13.1 1.49
22 100190939 LOC100190939 HypotheticalLOC100190939 13q14.13 1.60
23 4552 MTRR 5-methyltetrahydrofolate-homocysteinemethyltransferase reductase 5p15.3-p15.2 1.74
24 348751 LOC348751 Hypotheticalprotein LOC348751 2q33.1 1.78
25 7099 TLR4 Toll-likereceptor 4 9q32-q33 1.95
26 5789 PTPRD Proteintyrosine phosphatase, receptor type, D 9p23-p24.3 2.17
27 3043 HBB Hemoglobin,beta 11p15.5 1.82
28 146456 TMED6 Transmembraneemp24 protein transport domain containing 6 16q22.1 2.61
29 253039 LOC253039 HypotheticalLOC253039 9q33.2 1.32
30 2037 EPB41L2 Erythrocytemembrane protein band 4.1-like 2 6q23 1.81
31 59352 LGR6 Leucine-richrepeat-containing G protein-coupled receptor 6 1q32.1 2.28
32 2689 GH2 Growthhormone 2 17q24.2 1.42
33 4886 NPY1R NeuropeptideY receptor Y1 4q31.3-q32 4.03
34 283345 RPL13P5 Ribosomalprotein L13 pseudogene 5 12p13.31 1.99
35 3119 HLA-DQB1 Majorhistocompatibility complex, class II, DQ beta 1 6p21.3 1.55
36 140881 DEFB129 Defensin,beta 129 20p13 1.44
37 144568 A2ML1 Alpha-2-macroglobulin-like1 12p13.31 1.59
38 10783 NEK6 NIMA(never in mitosis gene a)-related kinase 6 9q33.3-q34.11 1.53
39 130399 ACVR1C ActivinA receptor, type IC 2q24.1 2.32
40 27283 TINAG Tubulointerstitialnephritis antigen 6p11.2-p12 1.97
41 116511 MAS1L MAS1oncogene-like 6p21 1.47
42 8908 GYG2 Glycogenin2 Xp22.3 1.73
43 145447 ABHD12B Abhydrolasedomain containing 12B 14q22.1 3.20
44 401577 LOC401577 Hypotheticalprotein LOC401577 Xp22.33 1.49
45 10887 PROKR1 Prokineticinreceptor 1 2p13.1 1.44
46 4889 NPY5R NeuropeptideY receptor Y5 4q31-q32 1.50
47 327657 SERPINA9 Serpinpeptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 1.37
48 4860 NP Nucleosidephosphorylase 14q13.1 1.47
49 1056 CEL Carboxylester lipase (bile salt-stimulated lipase) 9q34.3 1.49
50 81796 SLCO5A1 Solutecarrier organic anion transporter family, member 5A1 8q13.3 1.34
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Fold
Change
51 6289 SAA2 Serumamyloid A2 11p15.1-p14 2.29
52 171558 PTCRA PreT-cell antigen receptor alpha 6p21.3 1.31
53 8309 ACOX2 Acyl-CoenzymeA oxidase 2, branched chain 3p14.3 2.21
54 79857 FLJ13224 Hypotheticalprotein FLJ13224 12p11.21 1.28
55 9376 SLC22A8 Solutecarrier family 22 (organic anion transporter), member 8 1.33
56 7712 ZNF157 Zincfinger protein 157 Xp11.2 1.40
57 10 NAT2 N-acetyltransferase2 (arylamine N-acetyltransferase) 8p22 2.45
58 283422 C12orf36 Chromosome12 open reading frame 36 12p13.1 2.07
doi:10.1371/journal.pone.0030168.t002
Table 2. Cont.
Table 3. Down-regulated genes in colorectal tumors of African American patients.
No. Gene ID Gene Name Gene Title
Chromosome
Location
Fold
Change
1 57730 ANKRD36B Ankyrin repeatdomain 36B 2q11.2 0.48
2 23587 C17orf81 Chromosome 17open reading frame 81 17p13.1 0.44
3 415 ARSE Arylsulfatase E(chondrodysplasia punctata 1) Xp22.3 0.21
4 395 ARHGAP6 Rho GTPaseactivating protein 6 Xp22.3 0.58
5 146547 PRSS36 Protease, serine,36 16p11.2 0.36
6 161823 ADAL Adenosine deaminase-like 15q15.3 0.65
7 246778 IL27 Interleukin 27 — 0.36
8 644246 LOC644246 Hypothetical proteinLOC644246 17q21.31 0.42
9 79132 DHX58 DEXH (Asp-Glu-X-His)box polypeptide 58 17q21.2 0.54
10 51095 TRNT1 TRNA nucleotidyltransferase, CCA-adding, 1 3p25.1 0.60
11 55769 ZNF83 Zinc fingerprotein 83 19q13.3 0.65
12 64093 SMOC1 SPARC relatedmodular calcium binding 1 14q24.2 0.44
13 642946 LQK1 Hypothetical LOC642946 1q32.3 0.47
14 147645 VSIG10L V-set andimmunoglobulin domain containing 10 like 19q13.41 0.65
15 26150 RIBC2 RIB43A domainwith coiled-coils 2 22q13.31 0.48
16 57531 HACE1 HECT domainand ankyrin repeat containing, E3 ubiquitin protein ligase 0.60
17 5303 PIN4 Protein (peptidylprolylcis/trans isomerase) NIMA-interacting, 4 (parvulin) Xq13 0.62
18 8820 HESX1 HESX homeobox1 3p14.3 0.56
19 79609 C14orf138 Chromosome 14open reading frame 138 14q21.3 0.62
20 816 CAMK2B Calcium/calmodulin-dependent proteinkinase II beta 22q12|7p14.3-p14.1 0.64
21 1953 MEGF6 Multiple EGF-like-domains6 1p36.3 0.55
22 79682 MLF1IP MLF1 interactingprotein 4q35.1 0.51
23 51340 CRNKL1 Crooked neckpre-mRNA splicing factor-like 1 (Drosophila) 20p11.2 0.61
24 100287616 LOC100287616 Hypothetical proteinLOC100287616 15q24.1 0.54
25 201973 CCDC111 Coiled-coil domaincontaining 111 4q35.1 0.67
26 3712 IVD Isovaleryl CoenzymeA dehydrogenase 15q14-q15 0.62
27 4942 OAT Ornithine aminotransferase(gyrate atrophy) 10q26 0.60
28 57830 KRTAP5-8 Keratin associatedprotein 40306 11q13.4 0.50
29 388610 TRNP1 TMF1-regulated nuclearprotein 1 1p36.11 0.47
30 26152 ZNF337 Zinc fingerprotein 337 20p11.1 0.62
31 100287572 LOC100287572 Similar tohCG1996962 18q23 0.63
32 1427 CRYGS Crystallin, gammaS 3q25-qter 0.65
33 4435 CITED1 Cbp/p300-interacting transactivator,with Glu/Asp-rich carboxy-terminal domain, 1 Xq13.1 0.55
34 339318 ZNF181 Zinc fingerprotein 181 19q13.11 0.69
35 49856 WDR8 WD repeatdomain 8 1p36.3 0.71
36 221322 C6orf170 Chromosome 6open reading frame 170 6q22.31 0.70
37 284018 C17orf58 Chromosome 17open reading frame 58 17q24.2 0.62
doi:10.1371/journal.pone.0030168.t003
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expression data did not follow normal distribution.
Results
Identification of differentially expressed genes between
AA and EA CRC patients
Patient population characteristics for 43 AA and 43 EA patients
were matched by TNM staging (Table 1). The two populations
were similar in age, gender and tumor localization. Forty non-
tumor colon tissues (13 AAs and 27 EAs) were used for genetic
comparisons of normal colon gene expression between AAs and
EAs.
The comparison of gene expression profiles from AA and EA
tumors using SAM revealed 95 gene transcripts to be differentially
expressed between the two groups at FDRs of #5%. Fifty-eight
genes were up regulated (Table 2) and 37 down regulated
(Table 3) in tumor of AAs. We used Ingenuity Pathway Analysis
to assess disease and pathway associations of these 95 genes that
were differentially expressed in CRC tumors by race. The disease
association analysis revealed associations of differentially expressed
genes with genetic pathways that are linked to inflammatory
response, hepatic system disease, developmental disorders, genetic
disorders and neurologic disease (Table S1). The six top
associated pathways for differentially expressed genes are shown
in Fig. 1. Three of these six pathways are related to inflammatory
and immune response. Differentially expressed genes in the five
highest scoring networks are shown in Table 4. Top associated
network functions for differently expressed genes were: 1)
organismal injury and abnormalities, gene expression, cellular
development 2) lipid metabolism, small molecule biochemistry,
molecular transport 3) cellular assembly and organization, organ
development, carbohydrate metabolism 4) antigen presentation
and inflammatory response, cellular movement 5) behavior,
digestive system development and function, endocrine system
development and function. One of these networks (network 4;
antigen presentation and inflammatory response) is graphically
represented in Fig. 2. Seven of the nine genes in this network were
up regulated in AA patients (HLA-DQB1, IL33, PAK2,
PROKR1, SAA2, TLR4, ZNF234), and two genes were down
regulated (DHX58, IL27).
We also performed SAM analysis using non-tumor colon tissues
from AA and EA patients and did not see differential gene
expression (data not shown), suggesting that the changes we
identified are tumor microenvironment specific.
Validation of microarray results
In order to select a representative group of genes for qRT-PCR
validation of differentially expressed genes between AA and EA
CRC patients, we performed a 10-fold cross validation analysis
that resulted in the selection of following ten genes: CRYBB2,
PSPH, ADAL, VSIG10L, C17orf81, ANKRD36B, ZNF835,
ARHGAP6, TRNT1 and WDR8.
Expression of these ten genes was validated by qRT-PCR on an
independent test set of 28 CRC patients (10 AA and 18 EA). The
qRT-PCR results are shown in Fig. 3. Two of the 10 differentially
Table 4. Functional association of differentially expressed genes generated by IPA.
ID Focus Molecules in Network Score Focus Molecules Top Functions
1 ARSE, C6ORF170, CITED1, CRYBB2, CRYGS, EPB41L2, HBB (includes
EG:3043), HESX1, HLA-DQB1, IVD, NAT2, OAT, PTPRD, RPS26, ZNF83
28 15 Organismal Injury and Abnormalities, Gene
Expression, Cellular Development
2 ACVR1C, ATP7B, C17ORF81, GH2, GPR39, MLF1IP, NP, PIN4, PTCRA,
SLC22A8, TRNT1, TTC38, VANGL1,WDR8 (includes EG:49856)
26 14 Lipid Metabolism, Small Molecule Biochemistry,
Molecular Transport
3 ANKRD36B, CRNKL1, GYG2, KCNV1, KLHDC10, MEGF6, MTRR, NEK6,
PSPH, RIBC2, ZNF337
20 11 Cellular Assembly and Organization, Organ
Development, Carbohydrate Metabolism
4 DHX58, HLA-DQB1, IL27, IL33, PAK2, PROKR1, SAA2, TLR4, ZNF234 15 9 Antigen Presentation, Inflammatory Response,
Cellular Movement
5 CAMK2B, CEL, NPY1R, NPY5R, SCML4, UTS2 96 Behavior, Digestive System Development and
Function, Endocrine System Development and
Function
doi:10.1371/journal.pone.0030168.t004
Figure 1. Ingenuity analysis of top pathways affected in
differentially expressed genes between African Americans
and European Americans. Y-axis is an inverse indication of p-value
or significance. The Threshold line marks the p=0.05. (Note that 3 of 6
top pathways shown are related to inflammation and immune
response).
doi:10.1371/journal.pone.0030168.g001
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CRYBB2, p=0.0004 and PHSP, p=0.001 (Fig. 3; Panel A.).
Eight were down-regulated in AA vs. EA CRC patients;
VSIG10L, p=0.015; C17orf81, p=0.032; WDR8, p=0.002;
TRNT1, p=0.004; ANKRD36B, p=0.044; ARHGAP6,
p=0.049; ADAL, p=0.074; ZNF83, p=0.11; (Fig. 3; Panel
B.). The direction of change (up or down regulation) for the qRT-
PCR validated genes was in agreement with SAM results. Eight of
ten genes in the qRT-PCR validation study reached a statistically
significant level (p,0.05; CRYBB2, PSPH, C17orf81,
ANKRD36B, VSIG10L, WDR8, TRNT1 and ARHGAP6).
Discussion
The causes of the CRC disparity that exists between AA and EA
patients remain to be fully elucidated. Although most of the
research on this disparity has focused on socioeconomic factors,
recent findings strongly support the role of genetic and biological
factors. Genetic differences between AA and EA CRC patients
were reported for SNP association, for incidence of MSI and level
of gene methylation [4,14,15]. Any of these differences can result
in differential gene expression between AA and EA CRC patients.
In this study we analyzed the gene expression profiles of 86 tumors
from 43 AA and 43 EA patients. Significant differences in the
expression of genes related to immune response and inflammation
within the tumor micro-environment were identified between
these two groups. This interpretation was supported by both
disease association and pathway analyses. Most of the immune-
related genes had higher expression in tumors from African-
American patients than in those from European-American
patients. Although preliminary, these findings are novel and could
have implications for cancer therapy. From the present study, we
do not know why CRC from African-American patients would
have a different immunologic profile than tumors from European-
American patients. We hypothesize that the causes of these
differences are multifactorial. Chronic inflammation is thought to
be a causative factor in colorectal carcinogenesis [24,25]. It was
shown that an immune response signature in the liver of cancer
patients predicts metastasis and recurrence of hepato-cellular
carcinoma [26]. Thus, future studies should evaluate whether the
immunologic profile of CRC in African-American patients is a
predisposing factor for tumor progression and metastasis. Previous
investigations identified a two-gene tumor signature (CRYBB2
and PSPHL) that accurately differentiated between African-
Figure 2. Gene network involved in ‘‘Inflammatory Response’’ generated by IPA for differentially expressed genes between African
Americans and European Americans. Red symbols are assigned for up-regulated and green for down-regulated genes. Node shape corresponds
to the functional role of molecules as shown in the legend. Direct or indirect interactions are shown by complete or dashed lines.
doi:10.1371/journal.pone.0030168.g002
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Those two genes were also differentially expressed between
African-American and European American breast cancer patients
[28] In this study we found up-regulation of CRYBB2 and PSPH
gene in CRC of African-American patients. Mutations in the
CRYBB2 gene are also responsible for familial cataract [29].
PSPHL is a homolog of PSPH. Interestingly, PSPH is located on
chromosome 7p15.2, a chromosomal region known to have gain
of function related to advanced tumor stage in non-small-cell lung
adenocarcinoma [30]. It was shown that increased expression of
PSPH in non-small-cell lung cancer corresponds to clinical
response to treatment with erlotinib [31]. Thus, it is possible that
higher expression of PSPH contributes to CRC susceptibility in
AAs and that the levels of PSPH expression may be correlated
with response to anti-EGFR treatment. These possibilities will
have to be tested in future studies. Considering down-regulated
genes in AAs we found lower expression of the C17orf81 gene.
Down regulation of this gene was associated with colon cancer
[32], suggesting that lower expression of this gene can contribute
to more aggressive CRC in AAs. Other down regulated genes in
AAs include: TRNT1 (involve in RNA processing; [33]);
ARHGAP6 (promotes actin remodeling: [34]); WDR8 (facilitates
formation of multiprotein complexes: [35]). Considering the
cellular functions of these genes it is not hard to envision how
their expression may influence aggressiveness of CRC.
Whole-genome gene expression analysis experiments can be
prone to findings that are either unique to a selected patient
population or are artificially created by the applied technology. To
exclude the possibility of an artifact, two different approaches were
used to cross validate our gene expression data. First, we
compared our results of the differentially expressed genes between
86 tumors and 40 surrounding non-tumor tissues with those from
a published meta-analysis of five CRC gene expression datasets in
Oncomine [36,37,38,39,40]; Table S2. We found a very good
agreement between our results and the results of the other 5 meta-
analyses. Of the top 20 over-expressed genes in CRC tumors
across the 5 other meta-analyses (Oncomine; https://www.
oncomine.org), 15 were also found to be significantly up-regulated
(FDR, ,5%) in our study. Of the top 20 under-expressed genes in
CRC tumors across the 5 other meta-analyses, 17 were
significantly down-regulated (FDR, ,5%) in our study.
Second, we validated the expression of ten key genes via qRT-
PCR and confirmed differences in gene expression between CRCs
of AAs and EAs for eight of them.
In conclusion, the gene expression profile of CRC corresponds
to differences in tumor biology between African-American and
European-American patients. The implications of these differences
in disease aggressiveness and response to therapy should be
evaluated in future studies.
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